Navigating Multiple Myeloma
Balancing patient quality of life, fitness, and treatment impact can be challenging when managing multiple myeloma (MM). How can we make informed management decisions for people with MM, based on a growing wealth of clinical data and options?
This Learning Zone covers pathophysiology, unmet needs, and diagnostic and treatment challenges in MM, featuring expert insights on current key questions.
Further resources will be added over the next 12 months. You can check back here to:
- Read a comprehensive overview of MM, including key drivers of progression
- Stay up to date with congress highlights from EHA 2024 on MM, with patient case study–led discussions on the changing paradigm and patient-centric care
- Explore an interactive patient case study in relapsed/refractory MM, with expert insights from Elena Zamagni
of interest
are looking at
saved
next event
Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit–risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to Johnson & Johnson. Please refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country for further information.
This content has been sponsored by Johnson & Johnson. The content hosted on this platform is intended for educational purposes. Any data about non- Johnson & Johnson products are based on publicly available information. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country. This educational activity is intended for healthcare professionals only.
JOB CODE, DATE OF PREPARATION